GB-110

• Description :

  GB-110 is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 selectively induces PAR2-mediated intracellular Ca2+ release in HT29 cells with an EC50 of 0.28 μM[1].

• UNSPSC :

  12352005

• Target :

  Protease Activated Receptor (PAR)

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/gb-110.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CC=NO1)N[C@@H](CC2CCCCC2)C(N[C@@H]([C@@H](C)CC)C(NCC3=CC=CC(C(N4CCC(CN)CC4)=O)=C3)=O)=O

• Molecular Formula :

  C33H48N6O5

• Molecular Weight :

  608.77

• References & Citations :

  [1]Barry GD, et al. Novel agonists and antagonists for human protease activated receptor 2. J Med Chem. 2010 Oct 28;53 (20) :7428-40.|[2]Suen JY, et al. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110) . Br J Pharmacol. 2012 Mar;165 (5) :1413-23.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PAR2

• CAS Number :

  [1252806-70-4]